Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation
暂无分享,去创建一个
Baoying Huang | Mingxuan Xia | L. Vassilev | D. Heimbrook | C. Tovar | D. Knezevic | Dejan Knezevic | Christian Tovar | David C Heimbrook | Lyubomir T Vassilev | Baoying Huang | Mingxuan Xia
[1] D. Lane,et al. Exploiting the p53 pathway for cancer diagnosis and therapy. , 1999, British journal of cancer.
[2] A. Jochemsen,et al. Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53* , 2002, The Journal of Biological Chemistry.
[3] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[4] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[5] A. Levine,et al. Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.
[6] A. Levine,et al. The p53 pathway: positive and negative feedback loops , 2005, Oncogene.
[7] Hong Yang,et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.
[8] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[9] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[10] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[11] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[12] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[13] Guillermina Lozano,et al. MDM2, an introduction. , 2003, Molecular cancer research : MCR.
[14] T. Holak,et al. Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.
[15] Geng-Hung Liu,et al. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Chène. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.
[17] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[18] A. Levine,et al. MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.
[19] G. Stark,et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.
[20] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[21] Baoli Hu,et al. MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin* , 2006, Journal of Biological Chemistry.
[22] S. Francoz,et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[23] L. Vassilev. Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics , 2004, Cell cycle.
[24] K. Helin,et al. Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.
[25] G. Wahl,et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.
[26] A. Jochemsen,et al. Mdmx and Mdm2: Brothers in Arms? , 2004, Cell cycle.
[27] C. Prives,et al. Unleashing the power of p53: lessons from mice and men. , 2006, Genes & development.
[28] Pankaj Oberoi,et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. , 2005, Cancer cell.
[29] Hong Yang,et al. Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis*♦ , 2004, Journal of Biological Chemistry.
[30] Jean-Christophe Marine,et al. Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.
[31] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[32] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[33] Mengjia Tang,et al. Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.